-
Loading metrics
Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients
- Alessandra Bisagni,
- Maria Pagano,
- Sally Maramotti,
- Francesca Zanelli,
- Martina Bonacini,
- Elena Tagliavini,
- Luca Braglia,
- Massimiliano Paci,
- Andrea Mozzarelli,
- Stefania Croci
x
- Published: April 24, 2018
- https://doi.org/10.1371/journal.pone.0196350